Bone loss rate in adrenal incidentalomas: a longitudinal study.

Clinical and Research Unit of Endocrinology, Scientific Institute Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Foggia, Italy.
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.43). 11/2001; 86(11):5337-41. DOI: 10.1210/jc.86.11.5337
Source: PubMed

ABSTRACT Although by definition patients with adrenal incidentalomas (AI) do not have evident clinical syndromes, they may frequently suffer from subclinical hypercortisolism (SH). This is of some importance because of evidence that SH may lead to clinical complications, including bone loss. Thus, the understanding of bone involvement due to SH may be extremely important in the management of AI. Unfortunately, the available data on bone mineral density (BMD) in AI patients come from cross-sectional studies, which, to further complicate our understanding, are also conflicting, probably due to a different selection of patients and/or the variability in cortisol secretion (CS) often described in AI. To gain further insight about this topic, we performed a longitudinal study evaluating the rate of spinal and femoral bone loss levels in 24 females with AI. AI subjects were subdivided in two groups on the basis of the median of urinary cortisol secretion (UFC): group I (n = 12; UFC, <140.4 nmol/24 h) and group II (n = 12; UFC, >140.4 nmol/24 h). Spinal BMD was measured by both single energy quantitative computed tomography (L1-L4) and dual energy x-ray absorptiometry (DXA; L2-L4), and femoral BMD was determined by DXA. Bone loss rate was expressed as the change in z-score per yr. The spinal bone loss rate was higher (P < 0.005) in group II than in group I when measured by both quantitative computed tomography (-0.19 +/- 0.14 vs. 0.00 +/- 0.15) and DXA (-0.19 +/- 0.17 vs. 0.00 +/- 0.11). Moreover, CS and spinal bone loss rate were significantly correlated when patients were considered together. In conclusion, our data show that 1) AI patients with higher CS have increased lumbar trabecular bone loss rate than those with lower CS; and 2) the degree of spinal bone loss rate is related to the degree of CS. Thus, lumbar spine (LS) BMD has to be evaluated for well balanced decision-making on the treatment of choice for AI female patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Thyrotoxicosis and primary hyperaldosteronism both cause hypokalemic periodic paralysis. Here we report a 51-year-old woman presenting with severe hypokalemia due to both thyrotoxicosis and primary hyperaldosteronism. At first presentation, she had a potassium level of 1.5 mEq/L and thyrotoxicosis due to a hot nodule, and was diagnosed as having thyrotoxic hypokalemic periodic paralysis. After treatment with propylthiouracil and potassium, she completely regained muscle strength. Nevertheless, a decrease in potassium level was observed again when the replacement of potassium was discontinued. The further diagnostic work-up of the patient, who had also history of hypertention, revealed primary hyperaldosteronism and subclinical Cushing's syndrome due to adrenal adenoma on the left side. Whether thyrotoxicosis contributed to the hypokalemic periodic paralysis in this patient is a matter of debate. Adrenal hyperfunction should be considered in all patients with hypertension and hypokalemia regardless of the presentation of the case. Turk Jem 2009; 13: 87-90
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of high resolution imaging procedures has increased the identification of incidentally adrenal masses. When properly studied, adrenal incidentalomas show some biochemical features of adrenocortical autonomy in a significant number of cases, setting the basis for the diagnosis of subclinical Cushing syndrome. Recent evidences suggest that subtle glucocorticoid hypersecretion may be associated with metabolic syndrome, high cardiovascular risk and osteoporosis development. In fact, some patients with subclinical hypercortisolism due to adrenal incidentaloma get an improvement of hypertension and metabolic abnormalities following surgical treatment. These data raise several questions related to the need of evaluating and treating subclinical Cushing syndrome, specially when surgery can be performed by the less-aggressive laparoscopic approach. At present, the uniformity of diagnostic criteria, results of spontaneous follow-up and the effects of treatment of subclinical Cushing syndrome represent one of the most interesting challenges in adrenal pathology.
    Endocrinología y Nutrición 51(5):287–294.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The term adrenal incidentaloma covers a wide spectrum of adrenal pathologies sharing the method of discovery. The management of adrenal incidentaloma is controversial, and clinicians should determine whether the patient''s health is affected by the presence of a tumor. Critical points in management include differentiating benign from malignant and hormonally active from nonfunctional adrenal masses. The probability of malignancy is related to tumor size and imaging phenotype. Masses smaller than 4 cm in diameter that exhibit low attenuation by unenhanced CT scan and rapid contrast washout by delayed contrast-enhanced CT scan are probably benign. All patients with adrenal incidentaloma should undergo biochemical evaluations for pheochromocytoma and subclinical or overt Cushing''s syndrome, and hypertensive patients should undergo biochemical testing for hyperaldosteronism. Laparoscopic adrenalectomy is the treatment of choice in all hypersecretory tumors. If adrenocortical carcinoma is suspected, an open adrenalectomy is recommended. Patients who are not candidates for surgical resection of the tumor should be monitored radiographically for 2 years, and hormonal follow-up should be performed annually for 4 years.
    Expert Review of Endocrinology &amp Metabolism 10/2011; 6(6):811-817.

Full-text (2 Sources)

Available from
Jun 4, 2014

Similar Publications